Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Director | June 16, 2023 | June 20, 2023 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
| Seagen Inc.SGEN · Entity 13956 | EVP, Commercial | November 29, 2018 | November 30, 2018 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Commercial Officer | January 09, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IPI Legacy Liquidation Co
Report date June 16, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-06-15 | Direct | 13,222 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 13,222 · Balance 13,222 F1: The option is 100% vested on June 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is 100% vested on June 16, 2024.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Seagen Inc.
Report date November 29, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,556 |
Reported balance
After 2018-11-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-29 · Sale · Disposed 7,000 · Balance 72,556 F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.8711 to $62.9508. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.8711 to $62.9508. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Xenon Pharmaceuticals Inc.
Report date January 09, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.15 · Expires 2036-01-08 | Direct | 40,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 40,000 · Balance 40,000 F1: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 20,000 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 5,556 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.30 · Expires 2029-05-28 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 54,192 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 22,068 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 98,040 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 106,320 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 177,180 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 46,896 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 75,024 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 35,468 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,250 | $69.03 | $86,283.75 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 10 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,863 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 718 | $68.90 | $49,470.20 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 9 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,113 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,000 | $69.00 | $552,000.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 8 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 8,000 | $31.37 | $250,960.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 7 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 926 | $69.00 | $63,894.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 6 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 926 | $26.10 | $24,168.60 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 5 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 268 | $69.00 | $18,492.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 4 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 268 | $15.46 | $4,143.28 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 892 | $69.00 | $61,548.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 892 | $16.41 | $14,637.72 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001203311-18-000026 · edgardoc.xml · derivative · entry 5 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892 Underlying: Common Stock · 7,000 shares Expires 2020-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares vested at a rate of 25% on 10/29/2011 and monthly thereafter until all the shares were fully vested on 10/29/2014. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-18-000026 · edgardoc.xml · derivative · entry 4 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268 Underlying: Common Stock · 2,000 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 8/24/2012 and monthly thereafter until all the shares were fully vested on 8/24/2015. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 9,000 | $55.33 | $497,982.60 |
DisclosureSEC source: 0001203311-18-000026 · edgardoc.xml · nonDerivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $55.33 to $55.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 54 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2018. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,000 | $15.46 | $30,920.00 |
DisclosureSEC source: 0001203311-18-000026 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 54 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2018. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 7,000 | $16.41 | $114,870.00 |
DisclosureSEC source: 0001203311-18-000026 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 54 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2018. Read SEC document |
| May 03, 2018 Filed May 7, 2018 19:08 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,000 | $53.81 | $215,238.40 |
DisclosureSEC source: 0001203311-18-000024 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 F1 · price: Reflects sales of Common Stock executed in multiple transactions at prices ranging from $53.78 to $53.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission Staff, the Issuer or a Security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 21:36 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-qualified Stock Option (Right to buy) · Derivative | 8,333 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-18-008416 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2026-05-09 F1 · derivative.exercise_date: On May 9, 2016, the reporting person was granted an option to purchase 8,333 options of common stock. The performance criteria for this grant were met as of March 20, 2018 and the option shall vest in four (4) equal tranches on the first, second, third and fourth anniversaries of March 20, 2018 subject to continuous service with the Company as of each vesting date. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 20:17 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 1,399 | $55.58 | $77,755.86 |
DisclosureSEC source: 0001203311-18-000006 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,831 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,024 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-17-000074 · edgardoc.xml · derivative · entry 5 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268 Underlying: Common Stock · 5,024 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on August 24, 2012 and monthly thereafter until all the shares are fully vested on August 24, 2015. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,024 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001203311-17-000074 · edgardoc.xml · derivative · entry 4 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,024 shares Expires 2020-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on October 29, 2011 and monthly thereafter until all the shares are fully vested on October 29, 2014. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,024 | $51.94 | $260,966.66 |
DisclosureSEC source: 0001203311-17-000074 · edgardoc.xml · nonDerivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,230 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,024 | $15.46 | $77,671.04 |
DisclosureSEC source: 0001203311-17-000074 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,024 | $16.41 | $82,443.84 |
DisclosureSEC source: 0001203311-17-000074 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,907 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0001203311-17-000070 · edgardoc.xml · derivative · entry 4 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,907 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 2/29/2013 and monthly thereafter until all the shares were fully vested on 2/29/2016. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,662 | $52.51 | $244,794.16 |
DisclosureSEC source: 0001203311-17-000070 · edgardoc.xml · nonDerivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,206 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,907 | $52.52 | $152,672.15 |
DisclosureSEC source: 0001203311-17-000070 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,868 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $52.5175 to $52.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,907 | $18.46 | $53,663.22 |
DisclosureSEC source: 0001203311-17-000070 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 19:18 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,788 | $47.89 | $85,635.37 |
DisclosureSEC source: 0001203311-17-000058 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,868 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 20:12 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,344 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001203311-17-000042 · edgardoc.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,344 Underlying: Common Stock · 40,344 shares Expires 2027-08-17 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years form grant date. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 20:12 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 2,156 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001203311-17-000042 · edgardoc.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,156 Underlying: Common Stock · 2,156 shares Expires 2027-08-17 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years form grant date. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 20:12 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-17-000042 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,656 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Restricted stock units shall vest in full three (3) years from grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 18:52 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0001203311-17-000038 · edgardoc.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907 Underlying: Common Stock · 6,000 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 2/28/2013 and monthly thereafter until all the shares were fully vested on 2/28/2016. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 18:52 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,000 | $49.19 | $295,110.00 |
DisclosureSEC source: 0001203311-17-000038 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,656 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 105 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2017. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 18:52 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 6,000 | $18.46 | $110,760.00 |
DisclosureSEC source: 0001203311-17-000038 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 105 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2017. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 19:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,100 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001203311-16-000185 · edgardoc.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,024 Underlying: Common Stock · 3,100 shares Expires 2020-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 10/29/11 and monthly thereafter until all the shares were fully vested on 10/29/14. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 19:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 3,100 | $16.41 | $50,871.00 |
DisclosureSEC source: 0001203311-16-000185 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · derivative · entry 6 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926 Underlying: Common Stock · 10,000 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all shares were fully vested on 8/20/16. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,761 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · derivative · entry 5 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,761 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares vested at a rate of 25% on 2/28/13 and monthly thereafter until all shares were fully vested on 2/28/16. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,194 | $64.35 | $76,832.71 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · nonDerivative · entry 4 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,504 F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $63.75 to $64.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,761 | $18.46 | $50,968.06 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · nonDerivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,806 | $63.25 | $557,001.52 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,937 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.73 to $63.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 19:26 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 10,000 | $26.10 | $261,000.00 |
DisclosureSEC source: 0001203311-16-000183 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 19:09 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,167 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-16-000157 · edgardoc.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 19:09 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 4,167 | $15.46 | $64,421.82 |
DisclosureSEC source: 0001203311-16-000157 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 19:18 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 771 | $46.02 | $35,478.72 |
DisclosureSEC source: 0001203311-16-000151 · edgardoc.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,576 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 19:18 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,626 | $46.01 | $212,828.38 |
DisclosureSEC source: 0001203311-16-000151 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,347 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.